SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060398889> ?p ?o ?g. }

Showing items 1 to 100 of ±119 with 100 items per page.

W2060398889 endingPage "2591" @default.
W2060398889 startingPage "2579" @default.
W2060398889 abstract "ABSTRACT Aim: To confirm whether the aflibercept dose, plus docetaxel, in western study TCD6120 is appropriate for Chinese patients with nasopharyngeal carcinoma (NPC) and other solid tumors. Materials & methods: To assess dose-limiting toxicity of every 3-week 4 mg/kg or 6 mg/kg aflibercept plus 75 mg/m 2 docetaxel. Results: Previously treated patients (16 with NPC and 4 with lung cancer) were enrolled. At 6 mg/kg aflibercept: one dose-limiting toxicity was seen (neutropenic infection); the most frequently reported all-grade adverse events were oropharyngeal pain, stomatitis and alopecia; the most frequently reported grade 3/4 adverse events were oropharyngeal pain, stomatitis and neutropenic infection. Eleven patients had partial response and 3 had stable disease. Conclusion: Preliminary efficacy data for docetaxel/aflibercept are encouraging in Chinese patients with NPC. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry ( ClinicalTrials.gov , NCT01148615)." @default.
W2060398889 created "2016-06-24" @default.
W2060398889 creator A5006129010 @default.
W2060398889 creator A5009529797 @default.
W2060398889 creator A5012615010 @default.
W2060398889 creator A5014301491 @default.
W2060398889 creator A5017947172 @default.
W2060398889 creator A5022277705 @default.
W2060398889 creator A5026749521 @default.
W2060398889 creator A5042816586 @default.
W2060398889 creator A5043830460 @default.
W2060398889 creator A5048630778 @default.
W2060398889 creator A5062642936 @default.
W2060398889 creator A5066716873 @default.
W2060398889 creator A5072795022 @default.
W2060398889 creator A5082357190 @default.
W2060398889 creator A5082566314 @default.
W2060398889 creator A5086426839 @default.
W2060398889 creator A5091143438 @default.
W2060398889 date "2014-12-01" @default.
W2060398889 modified "2023-10-18" @default.
W2060398889 title "Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors" @default.
W2060398889 cites W1481846369 @default.
W2060398889 cites W1966162777 @default.
W2060398889 cites W2004494623 @default.
W2060398889 cites W2008086131 @default.
W2060398889 cites W2017286592 @default.
W2060398889 cites W2059275582 @default.
W2060398889 cites W2076733823 @default.
W2060398889 cites W2104648809 @default.
W2060398889 cites W2119629056 @default.
W2060398889 cites W2123595815 @default.
W2060398889 cites W2123769936 @default.
W2060398889 cites W2126937887 @default.
W2060398889 cites W2138787512 @default.
W2060398889 cites W2140040590 @default.
W2060398889 cites W2144750930 @default.
W2060398889 cites W2145238269 @default.
W2060398889 cites W2145835533 @default.
W2060398889 cites W2153972462 @default.
W2060398889 cites W2154197604 @default.
W2060398889 cites W2155912767 @default.
W2060398889 cites W2157769714 @default.
W2060398889 cites W2160982012 @default.
W2060398889 cites W2167224460 @default.
W2060398889 cites W4251333818 @default.
W2060398889 doi "https://doi.org/10.2217/fon.14.206" @default.
W2060398889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25531046" @default.
W2060398889 hasPublicationYear "2014" @default.
W2060398889 type Work @default.
W2060398889 sameAs 2060398889 @default.
W2060398889 citedByCount "1" @default.
W2060398889 countsByYear W20603988892020 @default.
W2060398889 crossrefType "journal-article" @default.
W2060398889 hasAuthorship W2060398889A5006129010 @default.
W2060398889 hasAuthorship W2060398889A5009529797 @default.
W2060398889 hasAuthorship W2060398889A5012615010 @default.
W2060398889 hasAuthorship W2060398889A5014301491 @default.
W2060398889 hasAuthorship W2060398889A5017947172 @default.
W2060398889 hasAuthorship W2060398889A5022277705 @default.
W2060398889 hasAuthorship W2060398889A5026749521 @default.
W2060398889 hasAuthorship W2060398889A5042816586 @default.
W2060398889 hasAuthorship W2060398889A5043830460 @default.
W2060398889 hasAuthorship W2060398889A5048630778 @default.
W2060398889 hasAuthorship W2060398889A5062642936 @default.
W2060398889 hasAuthorship W2060398889A5066716873 @default.
W2060398889 hasAuthorship W2060398889A5072795022 @default.
W2060398889 hasAuthorship W2060398889A5082357190 @default.
W2060398889 hasAuthorship W2060398889A5082566314 @default.
W2060398889 hasAuthorship W2060398889A5086426839 @default.
W2060398889 hasAuthorship W2060398889A5091143438 @default.
W2060398889 hasConcept C121608353 @default.
W2060398889 hasConcept C126322002 @default.
W2060398889 hasConcept C143998085 @default.
W2060398889 hasConcept C197934379 @default.
W2060398889 hasConcept C2776694085 @default.
W2060398889 hasConcept C2777802072 @default.
W2060398889 hasConcept C2778749236 @default.
W2060398889 hasConcept C2778997737 @default.
W2060398889 hasConcept C2779051857 @default.
W2060398889 hasConcept C2781190966 @default.
W2060398889 hasConcept C509974204 @default.
W2060398889 hasConcept C71924100 @default.
W2060398889 hasConcept C90924648 @default.
W2060398889 hasConceptScore W2060398889C121608353 @default.
W2060398889 hasConceptScore W2060398889C126322002 @default.
W2060398889 hasConceptScore W2060398889C143998085 @default.
W2060398889 hasConceptScore W2060398889C197934379 @default.
W2060398889 hasConceptScore W2060398889C2776694085 @default.
W2060398889 hasConceptScore W2060398889C2777802072 @default.
W2060398889 hasConceptScore W2060398889C2778749236 @default.
W2060398889 hasConceptScore W2060398889C2778997737 @default.
W2060398889 hasConceptScore W2060398889C2779051857 @default.
W2060398889 hasConceptScore W2060398889C2781190966 @default.
W2060398889 hasConceptScore W2060398889C509974204 @default.
W2060398889 hasConceptScore W2060398889C71924100 @default.
W2060398889 hasConceptScore W2060398889C90924648 @default.
W2060398889 hasIssue "16" @default.